Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.406
Neutral
RSI(14)
45.920
Neutral
STOCH(KDJ)(9,3,3)
21.599
Neutral
ATR(14)
1.262
Low Volatility
CCI(14)
-137.529
Sell
Williams %R
71.912
Sell
TRIX(12,20)
0.119
Sell
StochRSI(14)
75.065
Buy
Tonix Pharmaceuticals Holding Corp
TNXP16.340USD
+1.390+9.30%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
166.15MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Tonix Pharmaceuticals Holding Corp
Currency: USD Updated: 2026-02-06Key Insights
Tonix Pharmaceuticals Holding Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 112 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 66.33.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Tonix Pharmaceuticals Holding Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Tonix Pharmaceuticals Holding Corp Highlights
StrengthsRisks
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.09M.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.19M shares, increasing 27.69% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 6.14K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
66.333
Target Price
+343.70%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Tonix Pharmaceuticals Holding Corp is 7.02, ranking 132 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 3.29M, representing a year-over-year increase of 16.58%, while its net profit experienced a year-over-year increase of 125.22%.
Score
Financials
9.93
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.61
Operational Efficiency
2.88
Growth Potential
7.55
Shareholder Returns
7.15
Tonix Pharmaceuticals Holding Corp's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Tonix Pharmaceuticals Holding Corp is 8.02, ranking 33 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.00, which is -5366.67% below the recent high of 0.05 and -44066.67% above the recent low of -0.40.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 112/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Tonix Pharmaceuticals Holding Corp is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 65.00, with a high of 70.00 and a low of 64.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
66.333
Target Price
+343.70%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Tonix Pharmaceuticals Holding Corp
TNXP
2
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Tonix Pharmaceuticals Holding Corp is 1.30, ranking 158 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 19.22 and the support level at 14.20, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
16.380
Sell
MA10
17.196
Sell
MA20
17.066
Sell
MA50
17.112
Sell
MA100
18.822
Sell
MA200
26.731
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Tonix Pharmaceuticals Holding Corp is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 25.70%, representing a quarter-over-quarter increase of 39.67%. The largest institutional shareholder is The Vanguard, holding a total of 673.61K shares, representing 5.26% of shares outstanding, with 295.78% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Geode Capital Management, L.L.C.
Northern Trust Investments, Inc.
State Street Investment Management (US)
UBS Financial Services, Inc.
Capital Fund Management S.A.
Millennium Management LLC
Fidelity Management & Research Company LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tonix Pharmaceuticals Holding Corp is 4.26, ranking 91 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.88. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.88
VaR
+9.59%
240-Day Maximum Drawdown
+77.13%
240-Day Volatility
+122.45%
Return
Best Daily Return
60 days
+14.56%
120 days
+15.64%
5 years
+100.00%
Worst Daily Return
60 days
-11.27%
120 days
-21.97%
5 years
-100.00%
Sharpe Ratio
60 days
+0.16
120 days
-2.85
5 years
-0.56
Risk Assessment
Maximum Drawdown
240 days
+77.13%
3 years
+99.94%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+1.12
3 years
-0.33
5 years
-0.20
Skewness
240 days
-6.54
3 years
+1.19
5 years
+1.85
Volatility
Realised Volatility
240 days
+122.45%
5 years
+158.70%
Standardised True Range
240 days
+15.93%
5 years
+39320.80%
Downside Risk-Adjusted Return
120 days
-414.88%
240 days
-414.88%
Maximum Daily Upside Volatility
60 days
+64.34%
Maximum Daily Downside Volatility
60 days
+47.24%
Liquidity
Average Turnover Rate
60 days
+19.87%
120 days
+600.43%
5 years
--
Turnover Deviation
20 days
-99.88%
60 days
-99.92%
120 days
-97.48%
Peer Comparison
Pharmaceuticals
Tonix Pharmaceuticals Holding Corp
TNXP
5.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
